Paul E. Greenberg
 
                    Education
M.S., applied microeconomics and finance, MIT Sloan School of Management; M.A., economics, University of Western Ontario; A.B., economics, Vassar College
Summary of Experience
Paul E. Greenberg, Director of Analysis Group’s Health Care Practice, consults to pharmaceutical, biotechnology, and medical device companies in complex business litigation matters. Mr. Greenberg’s litigation experience has included performing economic and statistical analyses in support of testifying experts, as well as presenting findings to investigators from US Attorneys’ Offices and the Office of the Inspector General in numerous cases in which violations of the False Claims Act and/or the Anti-Kickback Statute have been alleged. Mr. Greenberg has provided economic consulting support in connection with class certification, liability, and damages in cases involving allegations of product failure, product fraud, antitrust, and/or patent infringement in the biopharmaceutical industry. He has provided strategic assistance to counsel at various key points in litigation, including pretrial discovery, settlement negotiations, and trial preparation. In the area of health economics and outcomes research (HEOR), Mr. Greenberg has undertaken cost-of-illness studies relating to numerous psychiatric and physical disorders, as well as pharmacoeconomic assessments of the cost-effectiveness of drugs based on data gathered in clinical trials and/or administrative claims files. Mr. Greenberg’s work in HEOR has been widely published in leading medical and health economics journals. He currently serves on the editorial boards of PharmacoEconomics, the Journal of Medical Economics, and Expert Opinion on Pharmacotherapy, and he previously served on the editorial boards of Law360’s Life Sciences and Health Care electronic newsletters.
- Analysis in NFL Players Association Deflategate Matter
- Analyzing Causation and Damages in Data Breach Litigation
- AstraZeneca v. TAP Pharmaceuticals, Inc.
- Comparison of Escitalopram and Citalopram
- Controlled Substance Monitoring and Effective Controls Against Diversion: Investigations and Settlements
- Costs Associated with ADHD Patients and Families
- Economic Burden of Opioid Abuse
- Mylan Pharmaceuticals v. Procter & Gamble Co.
- Pharmaceutical Off-Label Promotion & Kickbacks Settlements
- Quantifying the Economic Burden of Depression
- SmithKline v. Revenue Canada
- Steadfast Insurance Company v. Purdue Frederick Company
- United States of America et al ex rel Brown v Celgene Corp
- 
                                                        Impact of living with an adult with depressive symptoms among households in the United StatesJournal of Affective Disorders, 2024 
 2024Greenberg P, O'Callaghan L, Fournier AA, Gagnon-Sanschagrin P, Maitland J, Chitnis A 
- 
                                                        The Economic Burden of Adults with Major Depressive Disorder in the United States (2019)Advances in Therapy, 2023 
 2023Greenberg P, Chitnis A, Louie D, Suthoff E, Chen SY, Maitland J, Gagnon-Sanschagrin P, Fournier AA, Kessler RC 
- 
                                                        Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United StatesJournal of Clinical Psychiatry, 2022 
 2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P 
- 
                                                        Health Cos. Can Reduce FCA Risk by Leveraging DataLaw360, 2021 
 2021Jenny B, Yenikomshian M, Greenberg PE 
- 
                                                        
- 
                                                        The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)PharmacoEconomics, 2021 
 2021Greenberg P, Fournier A, Sisitsky T, Simes M, Berman R, Koenigsberg S, Kessler R 
- 
                                                        The Growing Burden of Major Depressive Disorders (MDD): Implications for Researchers and Policy MakersPharmacoEconomics (2021) 39:619–625 
 2021
- 
                                                        Special Issue of PharmacoEconomics on Major Depressive DisordersPharmacoEconomics (2021) 39:617 
 2021
- 
                                                        Healthcare resource utilization and costs associated with postpartum depression among commercially insured householdsCurrent Medical Research and Opinion, 2020 
 2020Epperson CN, Huang M, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A 
- 
                                                        US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort StudyPharmacoEconomics - Open, 2020 
 2020Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P 
- 
                                                        Medicaid spending burden among beneficiaries with treatment-resistant depressionJournal of Comparative Effectiveness Research, February 8, 2019 
 2019Pilon D, Sheehan J, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE 
- 
                                                        Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and ChallengesPharmacoEconomics, March 8, 2019 
 2019Thesmar D, Sraer D, Pinheiro L, Dadson N, Veliche R, Greenberg PE 
- 
                                                        
- 
                                                        Burden of treatment-resistant depression in Medicare: A retrospective claims database analysisPLOS One, 2019 
 2019Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE 
- 
                                                        Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims DatabaseJournal of Clinical Psychiatry. Feb 20 2018;79(2) 
 2018Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE 
- 
                                                        Tracing The Path To Health Care Investigation SettlementsLaw 360, April 17, 2017 
 2017
- 
                                                        Decision Making in a World of Comparative Effectiveness ResearchBook co-edited by Analysis Group 
 2017
- 
                                                        Introducing Decision Making in a World of Comparative Effectiveness ResearchDecision Making in a World of Comparative Effectiveness Research 
 2017
- 
                                                        Perspectives of Comparative Effectiveness Research from the World of Decision MakingDecision Making in a World of Comparative Effectiveness Research 
 2017
- 
                                                        Legal Considerations in a World of Comparative Effectiveness ResearchDecision Making in a World of Comparative Effectiveness Research 
 2017Kalb P, Greenberg P, Pike C 
- 
                                                        
- 
                                                        
- 
                                                        
- 
                                                        
- 
                                                        Viewing Recent Opioid Regulations In ContextLaw360, April 1, 2016 
 2016
- 
                                                        
- 
                                                        
- 
                                                        
- 
                                                        Can social media data lead to earlier detection of drug-related adverse eventsPharmacoepidemiology and Drug Safety, 2016 Sep 7 doi: 10.1002/pds.4090. [Epub ahead of print] 
 2016Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P. 
- 
                                                        The Growing Economic Burden of Depression in the U.S.Scientific American MIND Guest Blog, February 25, 2015 
 2015
- 
                                                        The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010)J Clin Psychiatry 2015 Feb;76(2):155-73 
 2015Greenberg P, Fournier A, Sisitsky T, Pike C, Kessler R 
- 
                                                        What Attorneys Should Know About FDA’s MedWatch DataLaw360, January 29, 2014 
 2014
- 
                                                        Big Data Can Yield Big Insights on Promotional PracticesLaw360, August 14, 2014 
 2014
- 
                                                        Brief of Antitrust Economists as Amici Curiae in Support of RespondentsAmicus Curiae Brief on Reverse Payment Settlements, February 28, 2013 
 2013Cockburn I, Cremieux P, Grabowski H, Greenberg P, Hubbard R, Hughes J, Snyder E, Stangle B 
- 
                                                        Little Guidance for Lower Courts in FTC v. ActavisToday's General Council, Aug/Sept 2013, Volume 10/Number 4 
 2013John L, Leckerman J, Greenberg P 
- 
                                                        Prioritizing Safety Versus Budget: FDA and CMS Adopt Different StancesFDLI Update, May/June 2012 
 2012
- 
                                                        An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are LowFDLI Update, January/February 2011 
 2011Wei E, Claggett B, Greenberg P, Wei LJ 
- 
                                                        Mortality and Nonadherence to AEDSSudden Unexpected Death in Epilepsy: Continuing the Global Conversation (Epilepsy Australia, Epilepsy Bereaved, and SUDEP Aware/North America, 2011) 
 2011Duh MS, Greenberg PE, Guerin A, Korves C 
- 
                                                        Assessing the Relationship Between Compliance with Antidepressant Therapy and Employer Costs Among Employees in the United StatesJournal of Occupational and Environmental Medicine; 52(2) : 115-124. 2010 
 2010Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux P, Greenberg P 
- 
                                                        Risk of Hepatotoxicity-Related Hospitalizations Among Patients Treated With Opioid-Acetaminophen Combination Prescription Pain MedicationsPain Med. 2010 Nov;11(11):1718-25 
 2010Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Viau-Latremouille D, Stangle B, Lafeuille M, Greenberg P 
- 
                                                        Introducing Perspectives on Comparative Effectiveness ResearchPharmacoeconomics. 2010 Oct 1;28(10):787-8. doi: 10.2165/11535820-000000000-00000 
 2010
- 
                                                        Perspectives on Comparative Effectiveness Research: Views from Diverse ConstituenciesPharmacoEconomics, 2010, vol. 28, issue 10 
 2010
- 
                                                        Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performanceDepress Anxiety. 2010;27(1):78-89 
 2010Birnbaum H, Kessler R, Kelley D, Ben-Hamadi R, Joish V, Greenberg P 
- 
                                                        Economic Analysis in Off-Label Promotion CasesLaw360 (published on February 9, 2009) 
 2009
- 
                                                        The Growing Role of Economic Analysis in Off-Label Promotion CasesRx Compliance Report, Vol. VIII, Issue 8, pp. 7 - 8 
 2009
- 
                                                        The Risks and Costs of Multiple-Generic Substitution of TopiramateNeurology 
 2009Duh M, Paradis P, Latremouille-Viau D, Greenberg P 
- 
                                                        Determinants of Direct Cost Differences among US Employees with Major Depressive Disorders Using AntidepressantsPharmacoEconomics 2009; 27(6) 
 2009Birnbaum H, Ben-Hamadi R, Greenberg P, Hsieh M, Tang J, Reygrobellet C 
- 
                                                        Legal and Economic Perspectives Concerning U.S. Government Investigations of Alleged Off-Label Promotion by Drug ManufacturersPharmacoEconomics, 2009 27 (8) 
 2009Greenberg P, Kalb P 
- 
                                                        ABA Pharmaceutical Industry Antitrust HandbookABA Pharmaceutical Industry Antitrust Handbook 
 2009Greenberg P, Mishol D, Sisitsky T, Bruno C 
- 
                                                        Antidepressant treatment patterns and costs among US employeesJ Med Econ. 2009 Mar;12(1):36-45 
 2009Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R 
- 
                                                        The economic implications of generic substitution of antiepileptic drugs: a review of recent evidenceExpert Opin Pharmacother. 2009 Oct;10(14):2317-28. Review 
 2009Duh M, Cahill K, Paradis P, Cremieux P, Greenberg P 
- 
                                                        Treatment persistence, healthcare utilization and costs in adult patients with major depressive disorder: a comparison between escitalopramJ Med Econ. 2009 Jun;12(2):124-35. doi: 10.3111/13696990903093537. 
 2009Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. 
- 
                                                        Drug Safety and Risk Management Practice: What Drug Companies Can DoFDLI Update 2008, Issue 3. With Permission from FDLI 
 2008Duh MS, Greenberg P, Antras L 
- 
                                                        Does Generic Substitution Always Make Sense?Journal of Medical Economics, Fall 2008 
 2008
- 
                                                        Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.PharmacoEconomics 2008;26(2):99-120. 
 2008Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE 
- 
                                                        Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric populationCurrent Medical Research and Opinion 2008;24(9):2587-2595 
 2008Wu E, Greenberg P, Yang E, Yu A, Erder M 
- 
                                                        Comparison of treatment persistence, hospital utilization, costs among major depressive disorder geriatric patients treated with escitalopramCurrent Medical Research and Opinion 2008;24(10):2805-13 
 2008Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder M 
- 
                                                        Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey ReplicationArchives of General Psychiatry. 2007;64:543-552. 
 2007Merikangas K, Akiskal H, Angst J, Greenberg P, Hirschfeld R, Petukhova M, Kessler R 
- 
                                                        The Role of Epidemiology in Drug Safety LitigationsFDLI Update 2007, Issue 6. With Permission from FDLI 
 2007Duh M, Greenberg P, Weiner J 
- 
                                                        Considering the costs of bipolar depressionBehav Healthc 2007 Jan;27(1):45-7 
 2007Kessler R, Akiskal H, Ames M, Birnbaum H, Greenberg P, Hirschfeld R, Wang P 
- 
                                                        Linking Administrative Claims Data with Archival Productivity Measures To Inform Employer Decision MakingIn R Kessler, P Stang (Eds.), Health and Work Productivity: Emerging Issues in Research and Policy. Chicago, IL: University of Chicago Press, Spring 2006 
 2006
- 
                                                        A Regulatory Perspective on Productivity Claims: Implications for Future Productivity ResearchIn R Kessler, P Stang (Eds.), Health and Work Productivity: Emerging Issues in Research and Policy. Chicago, IL: University of Chicago Press, Spring 2006 
 2006
- 
                                                        Prevalence and Effects of Mood Disorders on Work Performance in a Nationally Representative Sample of U.S. WorkersAm J Psychiatry 2006 Sep;163(9):1561-8 
 2006Kessler R, Akiskal H, Ames M, Birnbaum H, Greenberg P, Robert M, Jin R, Merikangas K, Simon G, Wang P 
- 
                                                        Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001: A Societal Perspective.Clin J Pain 2006 Oct;22(8):667-76 
 2006Birnbaum H, White A, Reynolds J, Greenberg P, Zhang M, Vallow S, Schein J, Katz N 
- 
                                                        Off-Label Marketing Investigations in the Pharmaceutical IndustryAnalysis Group Forum 
 2006
- 
                                                        Roundtable Discussion: Importance of Causation Analysis in Mass Tort CasesFDLI Update 2006, Issue 6. With Permission from FDLI 
 2006Greenberg P, Lykos G, Gourley S, Davies C 
- 
                                                        Generic Competition in the U.S. Pharmaceutical IndustryInternational Journal of the Economics of Business 2006 Feb;13(1):15-38 
 2006Birnbaum H, Bizan O, Grabowski H, Greenberg P, Saha A 
- 
                                                        Impact and Treatment of Anemia in the Elderly: Clinical, Epidemiological, and Economic PerspectivesExpert Review of Pharmacoeconomics & Outcomes Research 
 2006Duh M, Latypova A, Greenberg P 
- 
                                                        The Economic Burden of Depression: Societal and Patient PerspectivesBiology of Depression. From Novel Insights to Therapeutic Strategies 
 2005
- 
                                                        The economic burden of depression in the US: societal and patient perspectivesExpert Opin Pharmacother 2005 Mar;6(3):369-76 
 2005
- 
                                                        Costs of Attention Deficit-Hyperactivity Disorder (ADHD) in the US: Excess Costs of Persons with ADHD and Their Family Members in 2000Curr Med Res Opin 2005 Feb;21(2):195-206 
 2005Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR 
- 
                                                        The prevalence and effects of adult attention deficit, hyperactivity disorder on work performance in a nationally representative sample of workersJ Occup Environ Med. 2005 Jun;47(6):565-72 
 2005Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustün TB. 
- 
                                                        Depression and Fibromyalgia: Treatment and Cost When Diagnosed Separately or ConcurrentlyJ Rheumatol 2004 Aug;31(8):1621-9 
 2004Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F 
- 
                                                        Economic Implications of Treatment-Resistant Depression Among EmployeesPharmacoeconomics 2004;22(6):363-73 
 2004Greenberg P, Corey-Lisle P, Birnbaum H, Marynchenko M, Claxton A 
- 
                                                        Administrative Claims Data: A Valuable Tool in Pharmaceutical LitigationFDLI Update 2004, Issue 1. With Permission from FDLI 
 2004
- 
                                                        Incidence and Costs of Accidents among Attention-Deficit, Hyperactivity Disorder PatientsJ Adolesc Health. 2004 Oct;35(4):346.e1-9. 
 2004Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K. 
- 
                                                        What’s So Different about Anxiety Disorders (such as Phobias)?Phobias (vol. 7 of the World Psychiatric Association series "Evidence and Experience in Psychiatry"), John Wiley & Sons, Ltd:2004;337-339 
 2004
- 
                                                        
- 
                                                        The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?J Clin Psychiatry. 2003 Dec;64(12):1465-75. 
 2003Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK 
- 
                                                        The Economics of Women and Depression: An Employer PerspectiveJ Affect Disord. 2003 Mar;74(1):15-22. 
 2003Birnbaum HG, Leong SA, Greenberg PE 
- 
                                                        Lower Respiratory Tract Infections: Impact on the WorkplacePharmacoeconomics 2003;21(10):749-59. Erratum in: Pharmacoeconomics 2003;21(12):883 
 2003Birnbaum H, Morley M, Leong S, Greenberg P, Colice G 
- 
                                                        Economic Cost and Epidemiological Characteristics of Patients with Fibromyalgia ClaimsJ Rheumatol 2003 Jun;30(6):1318-25 
 2003Robinson R, Birnbaum H, Morley MA, Sisitsky T, Greenberg P, Claxton A 
- 
                                                        Economic Impact of Olanzapine Plus Fluoxetine Combination Therapy Among Patients Treated for Depression: A Pilot StudyPsychopharmacol Bull. 2003 Summer;37(3):90-8. 
 2003Corey-Lisle P, Birnbaum H, Greenberg P, Marynchenko M, Dube S 
- 
                                                        The economic burden of depression with painful symptomsJ Clin Psychiatry. 2003;64 Suppl 7:17-23. 
 2003Greenberg PE, Leong SA, Birnbaum HG, Robinson RL 
- 
                                                        Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysisJ Clin Psychiatry. 2003 Oct;64(10):1201-9. 
 2003Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA. 
- 
                                                        Attention-Deficit, Hyperactivity Disorder: Increased Costs for Patients and Their FamiliesJ Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1415-23. 
 2003Swensen AR1, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A 
- 
                                                        Productivity Loss Due to Irritable Bowel Syndrome—ReplyArch Intern Med. 2003;163(18):2249-2250 
 2003Greenberg P, Birnbaum H, Leong S, Pike C, Ben-Hamadi R, Barghout V, Frech F, Ofman J 
- 
                                                        The Economic Burden of Anxiety and Stress DisordersIn K Davis (Ed.), Neuropsychopharmacology: The Fifth Generation of Progress. Baltimore, MD: The American College of Neuropsychopharmacology and Lippincott Williams & Wilkins 2002;67:981-92 
 2002
- 
                                                        Economic Burden of Respiratory Infections in an Employed PopulationChest 2002 Aug;122(2):603-11 
 2002Birnbaum H, Morley M, Greenberg P, Colice G 
- 
                                                        Direct and Indirect Costs of Asthma to an EmployerJ Allergy Clin Immunol 2002 Feb;109(2):264-70 
 2002Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA. 
- 
                                                        Productivity and Medical Costs of Diabetes in a Large Employer PopulationDiabetes Care 2002 Jan;25(1):23-9 
 2002Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P 
- 
                                                        Identification of a claims data “signature” and economic consequences for treatment-resistant depressionJ Clin Psychiatry. 2002 Aug;63(8):717-26. 
 2002Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. 
- 
                                                        Cost of Depression: Current Assessment and Future DirectionsExpert Review of Pharmacoeconomics & Outcomes Research 2001 Oct;1(1):69-76 
 2001Greenberg P, Leong S, Birnbaum H 
- 
                                                        Assessing the Economic Impact of Psychiatric Disorders: Where to Begin?Expert Opin Pharmacother. 2001 Apr;2(4):641-52. 
 2001Greenberg PE, Leong SA, Birnbaum HG 
- 
                                                        The effects of chronic medical conditions on work loss and work cutbackJ Occup Environ Med 2001 Mar;43(3):218-25 
 2001Kessler R, Greenberg P, Mickelson K, Meneades L, Wang P 
- 
                                                        Pharmaceutical Spending and Health Outcomes in the United StatesInvesting in Health: The Social and Economic Benefits of Healthcare Innovation 2001; 14: 59-76 
 2001Cremieux P, Ouellette P, Meilleur M, Leong S, Greenberg P, Birnbaum H 
- 
                                                        Identification of Diabetes Patients Using Claims Data: An Economic AnalysisDrug Benefit Trends 2001 Nov;13(suppl B): 28-33 
 2001Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S 
- 
                                                        Impact of illness and its treatment on workplace costs: regulatory and measurement issuesJ Occup Environ Med 2001 Jan;43(1):56-63 
 2001Greenberg P, Birnbaum H, Kessler R, Morgan M, Stang P 
- 
                                                        Economic burden of pneumonia in an employed populationArch Intern Med 2001 Dec 10-24;161(22):2725-31 
 2001Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL 
- 
                                                        Depression and work productivity: the comparative costs of treatment versus nontreatmentJ Occup Environ Med 2001 Jan;43(1):2-9 
 2001Simon G, Barber C, Birnbaum H, Frank R, Greenberg P, Rose R, Wang P, Kessler R 
- 
                                                        
- 
                                                        Management of Major Depression in the Workplace: Impact on Employee Work LossDisease Management & Health Outcomes 2000;7(3):163-71 
 2000
- 
                                                        The impact of antidepressant use on social functioning: reboxetine versus fluoxetineInt Clin Psychopharmacol 2000 Sep;15(5):279-89 
 2000Venditti L, Arcelus A, Birnbaum H, Greenberg P, Barr C, Rowland C, Williamson T 
- 
                                                        Direct and Indirect Costs of Rheumatoid Arthritis to an EmployerJ Occup Environ Med 2000 Jun;42(6):588-96 
 2000Birnbaum H, Barton M, Greenberg P, Sisitsky T, Auerbach R, Wanke L, Buatti M 
- 
                                                        The Economics of Anxiety DisordersPsychiatric Times’ Mental Health Economics: Practical Information on Changes in the U.S. Health Care System 
 2000
- 
                                                        
- 
                                                        Savings in Direct Medical Costs from the Use of TOBI™ (Tobramycin Solution for Inhalation) in Patients with Cystic FibrosisClin Ther 2000 Jan;22(1):140-51 
 2000LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O 
- 
                                                        The economic burden of anxiety disorders in the 1990sJ Clin Psychiatry 1999 Jul;60(7):427-35 
 1999Greenberg P, Sisitsky T, Kessler R, Finkelstein S, Berndt E, Davidson J, Ballenger J, Fyer A 
- 
                                                        Using healthcare claims data for outcomes research and pharmacoeconomic analysesPharmacoeconomics 1999 Jul;16(1):1-8 
 1999Birnbaum H, Cremieux P, Greenberg P, LeLorier J, Ostrander J, Venditti L 
- 
                                                        
- 
                                                        Pharmacoeconomics and health policy: Current applications and prospects for the futurePharmacoeconomics 1999 Nov;16(5 Pt 1):425-32 
 1999Greenberg P, Arcelus A, Birnbaum H, Cremieux P, LeLorier J, Ouellette P, Slavin M 
- 
                                                        Depression in the workplace: effects on short-term disabilityHealth Aff 1999 Sep-Oct;18(5):163-71 
 1999Kessler R, Barber C, Birnbaum H, Frank R, Greenberg P, Rose R, Simon G, Wang P 
- 
                                                        Workplace Burden of Depression: Case Study in Social Functioning Using Employer Claims DataDrug Benefit Trends 1999; 11 (8): 6-12 
 1999Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T 
- 
                                                        Workplace performance effects from chronic depression and its treatmentJ Health Econ 1998 Oct;17(5):511-35 
 1998Berndt E, Finkelstein S, Greenberg P, Howland R, Keith A, Rush A, Russell J, Keller M 
- 
                                                        The Next Phase of Managed Care: Targeting Investments in Employee HealthOn Managed Care 1997 Sept 
 1997Greenberg P, Berndt E, Finkelstein S 
- 
                                                        Price Growth of prescription pharmaceutical preparations: an update and extension.Competitive Strategies in the Pharmaceutical Industry 
 1996Berndt E, Greenberg P 
- 
                                                        How Much Does Depression Cost Society?The Harvard Mental Health Letter 
 1996Greenberg P, Finkelstein S 
- 
                                                        Depression in the Workplace: An Economic PerspectiveSelective Serotonin Re-Uptake Inhibitors 
 1996Greenberg P, Kessler R, Nells T, Finkelstein S, Berndt E 
- 
                                                        Improvement in subjective work performance after treatment of chronic depression: some preliminary resultsChronic Depression Study Group. Psychopharmacol Bull 1996;32(1):33-40 
 1996Finkelstein S, Berndt E, Greenberg P, Parsley R, Russell J, Keller M 
- 
                                                        Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an IndustryThe National Law Journal 1995 Sept. 
 1995Danzon P, Stamm L, Greenberg P 
- 
                                                        Economic consequences of illness in the workplaceSloan Management Review 1995 Summer 
 1995Greenberg P, Finkelstein S, Berndt E 
- 
                                                        Calculating the workplace cost of chronic diseaseBus Health 1995 Sep;13(9):27-8 
 1995Greenberg P, Finkelstein S, Berndt E 
- 
                                                        Consolidation and Restructuring: The Next Step in Managed CareHealth Care Manag 1995 Oct;2(1):221-35 
 1995Greenberg P, Danzon P, Stamm L 
- 
                                                        
- 
                                                        The Economic Burden of Depression in 1990Journal of Clinical Psychiatry 1993 Nov. 
 1993Greenberg P, Stiglin L, Finkelstein S, Berndt E 
- 
                                                        Depression: a Neglected Major IllnessJ Clin Psychiatry 1993 Nov;54(11):419-24 
 1993Greenberg P, Stiglin L, Finkelstein S, Berndt E 
- 
                                                    April 12, 2022
- 
                                                    June 14, 2021
- 
                                                    June 7, 2021
- 
                                                    May 5, 2021
- 
                                                    March 16, 2021
 
         
                                 
                                 
                                 
                                 
                                 
                                 
                                